Pharmacotherapy of XXXX .

@entity1 @entity22952 @entity712 @entity452 @entity859 @entity384 @entity1951 @entity3999 @entity6838 @entity955 @entity6759 @entity15726
The pharmacological treatment of @entity384 overlaps with the treatment of @entity712 . The primary objective of this treatment is to slow the progression of disease and improve quality and length of life. All @entity1 , including those with asymptomatic dysfunction of the left ventricle, ought to receive angiotensin converting enzyme inhibitors, (in the case of intolerance, angiotensin receptor blockers), and beta blockers. The results of studies involving aliskiren have been, so far, disappointing. In symptomatic @entity712 NYHA II-IV diuretics and mineralcorticoid receptor antagonists should be added to treatment. @entity6838 is recommended in the event of @entity955 , and otherwise only in the event of NYHA III and IV. @entity15726 is recommended for @entity1 with sinus rhythm and pulse rate of > 70/min. In decompensation of @entity712 , @entity452 , phosphodiesterase inhibitors or @entity6759 are administered over the short-term. Of the recent treatment options, the @entity1951 blocker and @entity859 A1 receptor antagonist ( @entity22952 ) were disappointing. One treatment with potential for the future is omecamtiv mecarbil, a heart @entity3999 activator.
